SCHEMBL19852425

SCHEMBL19852425

Fc1ccc(OC2CCCN(CC3COc4ccccc43)CC2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 2/20 0.42
HTR2A P28223 1/20 0.42
ADRB2 P07550 1/20 0.40
PLA2G1B P04054 1/20 0.37
ATG4B Q9Y4P1 1/20 0.37
HRH1 P35367 1/20 0.37
CCR3 P51677 1/20 0.37
HTR1A P08908 1/20 0.37
SIGMAR1 Q99720 1/20 0.37
ADRA2A P08913 2/20 0.37
ADRA2C P18825 2/20 0.37
ADRA1B P35368 2/20 0.37
ADRA2B P18089 1/20 0.37
ADRA1D P25100 1/20 0.37
ADRA1A P35348 1/20 0.37
SCN1A P35498 1/20 0.37
SCN2A Q99250 1/20 0.37
SCN3A Q9NY46 1/20 0.37
KCNH2 Q12809 1/20 0.36
MCHR1 Q99705 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21072473 0.96 HTR7 (0.42) HTR7HTR2AADRB2PLA2G1BATG4B
SCHEMBL19838628 0.86 HTR2A (0.41) HTR7HTR2AADRB2PLA2G1BATG4B
Hydrochloric Acid SCHEMBL19838581 0.85 HTR2A (0.41) HTR7HTR2AADRB2PLA2G1BATG4B
SCHEMBL19852330 0.85 HTR7 (0.45) HTR7HTR2AADRB2PLA2G1BATG4B
SCHEMBL19852469 0.82 PPARG (0.40) HTR1ASIGMAR1ADRA2AADRA2CADRA1B
SCHEMBL19839851 0.81 HTR7 (0.50) HTR7HTR2AADRB2PLA2G1BATG4B
SCHEMBL19852127 0.80 GAA (0.36) HTR7HTR2ASIGMAR1GAAHRH3
Hydrochloric Acid SCHEMBL19839831 0.80 HTR7 (0.49) HTR7HTR2AADRB2PLA2G1BATG4B
SCHEMBL21071623 0.78 HTR7 (0.45) HTR7HTR2AADRB2PLA2G1BATG4B
SCHEMBL19852460 0.78 KCNH2 (0.46) HTR1ASIGMAR1ADRA2AADRA2CADRA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11186564-B2 Dual NAV1.2/5HT2a inhibitors for treating CNS disorders SUNOVION PHARMACEUTICALS INC. (US) 2021-11-30 US disclosed
US-11186564-B2 Dual NAV1.2/5HT2a inhibitors for treating CNS disorders SUNOVION PHARMACEUTICALS INC. (US) 2021-11-30 US disclosed
US-20190194163-A1 DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS SUNOVION PHARMACEUTICALS INC. (US) 2019-06-27 US disclosed
US-20190194163-A1 DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS SUNOVION PHARMACEUTICALS INC. (US) 2019-06-27 US disclosed
WO-2018026371-A1 DUAL NAV1.2/5HT2A INHIBITORS FOR TREATING CNS DISORDERS SUNOVION PHARMACEUTICALS INC. (US) 2018-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190194163-A1 DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS SCN2A, HTR2A, HTR2C HTR7 112/4885HTR2A 2/4885ADRB2 152/4885
US-11186564-B2 Dual NAV1.2/5HT2a inhibitors for treating CNS disorders SCN2A, HTR2A, HTR2C HTR7 112/4885HTR2A 2/4885ADRB2 152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.